Report Overview

The Canada Anti-obesity drug market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.

According to the 2015 Canadian Health Measures Survey, 30% or more than one in three adults in Canada has obesity and may require medical support to manage their disease. In 2018, 26.8% of Canadians 18 and older (roughly 7.3 million adults) reported height and weight that classified them as obese. Another 9.9 million adults (36.3%) were classified as overweight bringing the total population with increased health risks due to excess weight to 63.1% in 2018. This was an increase from 2015, where 61.9% of Canadians aged 18 and older were overweight or obese. Overall, the proportion of adults who were overweight or obese was higher among males (69.4%) than among females (56.7%). The proportion who were overweight or obese was higher for males for all age groups starting at age 20. Obesity has incubated a sedentary lifestyle among the population to practice social distancing and severe lockdowns. The healthcare organization has issued a guideline and recommendation for the management of overweight/ obese patients as they have a greater probability of contracting the disease.



Market Drivers

The increasing prevalence of obesity is propelling the demand for these drugs in Canada. The growing awareness among the patient about the weight gains and associated impacts on other health disorders is attracting the patients towards this medication. The increasing adoption of a sedentary lifestyle and unhealthy diet plans along with the lack of exercise has led to increased body weight and adoption of anti-obesity drugs. The lack of weight management among the people and false mindsets of the people are the two factors restraining the growth of these markets.